MDeyes Once Daily AREDS 2 for Macular Defence                 

MDeyes is a macular defence formula based on the breakthrough clinical research of the Age-Related Eye Disease Study 2 (AREDS 2).(1)  This high quality supplement delivers the AREDS 2 low zinc formula in a simple Once Daily dosage.  MDeyes is available as either a convenient and affordable Once Daily soft gel capsule, or as a great-tasting Once Daily powdered orange drink.

   or call 1300 95 2001 or 07 3056 0960 for more information


Macular Health and AREDS 2

The macula is a small spot in the centre of the retina that processes sharp, clear, central vision. When you look directly at something, light is focused on the macula, allowing you to see detail and colour. Reading, driving, watching television, recognizing faces – all of these abilities are dependent on a healthy macula.

The Age Related Eye Disease Study (AREDS) is the extensive research study conducted by the National Eye Institute in the United States, which examined the role of nutritional supplementation in macular eye health. In 2013, the results of the updated AREDS 2 research were published after several years of comprehensive clinical trials, involving more than 4200 participants. AREDS 2 results indicated that antioxidant nutrients and Zinc, together with Lutein and Zeaxanthin, may help defend against free radical damage to the macular region and help support the protective macular pigment of the retina.



About Us

MDeyes is a product of MD EyeCare Pty Ltd, an Australian private healthcare company dedicated to developing formulations that are scientifically supported by strong clinical evidence.  

MDeyes is made in Australia under the highest therapeutic manufacturing standard and using only quality ingredients. It is made available direct to consumers on the recommendation of healthcare professionals, allowing us to deliver highly effective, evidence-based products at an affordable price.




(1) AREDS 2 - Age-Related Eye Disease Study 2 Research Group. JAMA. 2013;309:2005-2015. The AREDS 2 clinical trial was conducted by the National Eye Institute in the United States.